BCYC
Price
$3.71
Change
+$0.03 (+0.82%)
Updated
Sep 28 closing price
Capitalization
257.92M
30 days until earnings call
Intraday BUY SELL Signals
KURA
Price
$10.61
Change
-$0.15 (-1.39%)
Updated
Sep 28 closing price
Capitalization
957.22M
30 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCYC vs KURA

BCYC vs KURA Comparison Chart in %
View a ticker or compare two or three
VS
BCYC vs. KURA commentary
Sep 29, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Buy and KURA is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
BCYC vs KURA: Fundamental Ratings
BCYC
KURA
OUTLOOK RATING
1..100
6172
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
7948
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (9) in the null industry is somewhat better than the same rating for KURA (64) in the Biotechnology industry. This means that BCYC’s stock grew somewhat faster than KURA’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as KURA (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to KURA’s over the last 12 months.

BCYC's SMR Rating (97) in the null industry is in the same range as KURA (99) in the Biotechnology industry. This means that BCYC’s stock grew similarly to KURA’s over the last 12 months.

KURA's Price Growth Rating (48) in the Biotechnology industry is in the same range as BCYC (79) in the null industry. This means that KURA’s stock grew similarly to BCYC’s over the last 12 months.

KURA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BCYC (100) in the null industry. This means that KURA’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCKURA
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
69%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 15 days ago
77%
Bullish Trend 11 days ago
80%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 1 day ago
82%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
74%
COMPARISON
Comparison
Sep 29, 2026
Stock price -- (BCYC: $3.68 vs. KURA: $10.61)
Brand notoriety: BCYC and KURA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 62% vs. KURA: 78%
Market capitalization -- BCYC: $257.92M vs. KURA: $957.22M
BCYC [@Biotechnology] is valued at $257.92M. KURA’s [@Biotechnology] market capitalization is $957.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.37B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green while KURA’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • KURA’s FA Score: 0 green, 5 red.
According to our system of comparison, KURA is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 4 TA indicator(s) are bullish while KURA’s TA Score has 3 bullish TA indicator(s).

  • BCYC’s TA Score: 4 bullish, 6 bearish.
  • KURA’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than KURA.

Price Growth

BCYC (@Biotechnology) experienced а +0.96% price change this week, while KURA (@Biotechnology) price change was -8.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.95%. For the same industry, the average monthly price growth was -7.16%, and the average quarterly price growth was +4.45%.

Reported Earning Dates

BCYC is expected to report earnings on Oct 29, 2026.

KURA is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (+0.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BCYC
Daily Signal:
Gain/Loss:
KURA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CMG31.850.52
+1.66%
Chipotle Mexican Grill
EDUC1.30N/A
N/A
Educational Development Corp
MNSB24.76-0.07
-0.28%
MainStreet Bancshares
TNGX24.30-0.62
-2.49%
Tango Therapeutics
GRPN19.74-1.56
-7.32%
Groupon

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with DNLI. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+0.68%
DNLI - BCYC
49%
Loosely correlated
+2.89%
PCVX - BCYC
48%
Loosely correlated
+3.66%
NGNE - BCYC
46%
Loosely correlated
+0.60%
SANA - BCYC
46%
Loosely correlated
-0.51%
KURA - BCYC
45%
Loosely correlated
-1.39%
More